Introduction
============

Hepatitis C virus (HCV) was identified in 1989 as a major cause of parenterally transmitted non-A non-B hepatitis. Chronic HCV infection is characterized by varying degrees of inflammation and hepatic fibrosis.[@b1-dddt-9-799] The World Health Organization estimates that about 3% of the world's population is infected with HCV and that there are more than 170 million chronically HCV-infected patients, with about 3--4 million persons newly infected each year.[@b1-dddt-9-799]--[@b3-dddt-9-799] Prevalence rates vary widely, ranging from 0.15% in Scandinavia to about 15% in Egypt.[@b4-dddt-9-799],[@b5-dddt-9-799]

In newly infected patients, chronic infection develops in about 80% of cases, with 10%--20% developing cirrhosis and 1%--5% developing liver cancer over a period of 20--30 years.[@b5-dddt-9-799],[@b6-dddt-9-799] Until the very recent discovery of direct-acting antiviral drugs, and up to the time of writing this report, the gold standard therapy for chronic HCV in Egypt (approximately 90% of which is genotype 4) is a combination of PEGylated-interferon alfa and ribavirin, which results in a sustained virological response rate in about 50%--60% of patients after 48 weeks of therapy.[@b6-dddt-9-799]--[@b9-dddt-9-799]

In addition to its several contraindications, poor tolerability, and fairly common adverse effects, the current interferon-based treatment for chronic HCV is inadequately effective and also expensive for most patients in developing countries.[@b6-dddt-9-799],[@b7-dddt-9-799]

Patients with genotype 1 infection have a 42%--51% probability of achieving a sustained virological response after a 48-week course of therapy, while about 78%--82% of those infected with genotype 2 or 3, excluding those with a very high virus load, have been shown to respond to 24 weeks of treatment.[@b10-dddt-9-799],[@b11-dddt-9-799] One paper reported that about 13% of nonresponders to prior standard interferon-based therapy and 58.5% of patients who relapsed in general, responded to retreatment.[@b12-dddt-9-799]

Increased understanding of the lifecycle of HCV has resulted in the discovery of several targets for antiviral therapy, including the NS3/4A (protease), the NS5B (polymerase), NS5A, and HCV-hepatocyte cell entry mechanisms. The possibility of developing an interferon-free regimen for difficult-to-treat genotypes is believed to need a combination of different drug classes to provide high antiviral efficacy, good clinical and quality of life benefits, and a high barrier to resistance.

Herbal medicine is a popular complementary or alternative therapy in people with chronic liver disease. Many herbal products had been studied in vitro and in animal models, and been demonstrated to have hepatoprotective effects, and there have been reports of their clinical benefits in humans from many countries, from the Far East to the West.[@b13-dddt-9-799]--[@b19-dddt-9-799] Glycyrrhizin extract, as an example, has been shown to have good effects in the treatment of chronic viral hepatitis.[@b20-dddt-9-799]--[@b24-dddt-9-799] Turmeric (curcumin) was found to inhibit entry of HCV into human hepatocytes independent of genotype by affecting membrane fluidity, thus impeding virus binding and fusion.[@b25-dddt-9-799] Curcumin was also found to decrease HCV gene expression via suppression of Akt-SREBP-1 activation.[@b26-dddt-9-799]

*Eclipta alba* extract was demonstrated to strongly inhibit the RNA-dependent RNA polymerase activity of HCV replicase. It effectively inhibited HCV replication, resulting in a reduced HCV RNA titer and lower translation levels of viral proteins.[@b27-dddt-9-799] Further, treatment with *Tinospora cordifolia* extract was found to have immunomodulatory activity in many studies, and to protect the liver, as indicated by a significant reduction in serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and bilirubin in CCl~4~-intoxicated rats.[@b28-dddt-9-799],[@b29-dddt-9-799]

Viron^®^ is a herbal drug manufactured by European Egyptian Pharmaceutical Industries (Alexandria, Egypt) as a film-coated tablet formulation. It is a mixture of herbs with known hepatoprotective and antiviral properties. Each 1 g film-coated tablet contains dried powdered *T. cordifolia* (whole plant) 200 mg, *Glycyrrhiza glabra* (root) 100 mg, *Elettaria cardamomum* (seeds) 200 mg, *Curcuma longa* (rhizome) 200 mg, *E. alba* (whole plant) 200 mg, and *Rumex crispus* (whole plant) 100 mg.

Viron has been studied for acute, subacute, and chronic toxicity in three species of laboratory animals. The results confirmed the absence of toxic, teratogenic, mutagenic, and carcinogenic effects or other adverse effects, including effects on fertility, after repeated administration in mice, rats, and dogs for 3 months at very high doses up to several times the recommended maximum dose for humans (El-Eshmawy, unpublished data, 2007). A small, unpublished pilot study in human volunteers with chronic HCV has shown improved clinical status, quality of life, and serum markers.

Our research group is committed to scientific evaluation of the benefits and risks of agents commonly used as complementary and alternative medicines. We have designed a common protocol to study the safety and efficacy of some of these botanical agents in the treatment of chronic HCV. This study was conducted according to the same study design, eligibility criteria, and outcome measures that we applied and described in our previously published research[@b5-dddt-9-799] to explore the safety and any clinical or quality of life benefits offered by Viron tablets in patients with chronic HCV infection.

Materials and methods
=====================

This clinical trial was conducted according to a prospective, randomized, open-label, comparative design with a mean follow-up duration of 6 months. It was carried out in two outpatient clinics in Cairo and Alexandria, and in accordance with the recommendations of the Declaration of Helsinki and the International Conference on Harmonisation guidelines for good clinical practice. The protocol was approved by the local research ethics committee of the Green Clinic and Research Center, Alexandria, Egypt and all patients signed informed consents before any intervention. Eighty-two consecutive patients presenting to our outpatient clinics from May 2007 to March 2009 with documented chronic HCV infection or newly diagnosed HCV were entered into the study.

The inclusion criteria[@b5-dddt-9-799] were: male or female sex; age 18--60 years; chronic HCV infection with a polymerase chain reaction-positive test with or without elevated liver enzymes; interferon-naïve (not previously treated with interferon alone or in combination with ribavirin therapy); relapse of HCV (patients with a transient biochemical or virological response to previous interferon or combined therapy); nonresponse (patients who did not respond to previous interferon or combined therapy). The exclusion criteria[@b5-dddt-9-799] were: hepatitis B or other type of hepatitis; coinfection with human immunodeficiency virus or active schistosomiasis; alcohol or drug dependence or use during at least a year before the study; critical illness with severe hepatic decompensation or multiorgan failure; inability to swallow tablets or to comply with the study protocol for another reason; refusal to participate or sign informed consent; and pregnancy or lactation.

Eligibility criteria were verified from the patient history, clinical examination, and the following confirmatory tests: detection of HCV-RNA by qualitative and quantitative polymerase chain reaction measurements; screening test for HBV surface antigen, schistosome antigens, and human immunodeficiency virus by enzyme-linked immunosorbent assay; upper abdominal and liver ultrasonography; and liver and kidney function tests, a pregnancy test, and complete blood count.

Patients fulfilling the inclusion/exclusion criteria were enrolled in the study and randomly allocated to 6 months of treatment with Viron one tablet twice daily (group 1), two tablets twice daily (group 2), or three tablets twice daily (group 3). All patients were followed up monthly with a physical examination, assessment of quality of life (Chronic Liver Disease Questionnaire \[CLDQ\] score), hematological studies, hepatic and renal function tests, and ultrasonography of the liver. Quantitative polymerase chain reaction RNA tests were performed at 3 and 6 months.

Endpoints
---------

The study endpoints were: Early and end of treatment virological response (ETR; defined as complete \[loss of detectable HCV-RNA\] or partial \[\>2 log virus load reduction\]) at months 3 and 6.Biochemical response (normalization or significant reduction of transaminases) at the end of treatment.Improvement of health-related quality of life scores using the CLDQ developed by Younossi et al.[@b30-dddt-9-799],[@b31-dddt-9-799] The CLDQ includes 29 items in the following domains: abdominal symptoms, fatigue, systemic symptoms, activity, emotional function, and worry. Responses on the CLDQ were graded on a scale of 1 ("all of the time" \[worst\]) to 7 ("none of the time" \[best\]). The change in the final CLDQ overall score from baseline was compared. The CLDQ overall score is calculated by dividing the total score by the total number of items (29).[@b30-dddt-9-799],[@b31-dddt-9-799]Incidence of adverse events and toxicity.[@b5-dddt-9-799]

Statistical analysis
--------------------

The data were analyzed using Statistical Package for the Social Sciences version 12 software (SPSS Inc, Chicago, IL, USA). Paired quantitative variables were compared before and after using the paired-samples *t*-test. The three independent treatment groups were compared by one-way analysis of variance, Tukey's test for post hoc analysis, and analysis of covariance for adjustment for covariates. The Chi-squared/Fisher's Exact tests were used for analysis of categorical variables.

Results and discussion
======================

Sixty consecutive eligible assessable patients were included in the study analysis. Eligible patients were randomly allocated to three treatment groups using a block randomization technique. Group 1 received a low dose of Viron (one tablet twice daily), group 2 received a medium dose (two tablets twice daily), and group 3 received a high dose (three tablets twice daily). All patients were followed up for 6 months. [Figure 1](#f1-dddt-9-799){ref-type="fig"} shows the patient disposition from screening to analysis ([Figure 1](#f1-dddt-9-799){ref-type="fig"}). Our variables were mostly quantitative, so the analysis was performed on a per protocol basis, given the small and balanced number of patients who dropped-out from each group. Baseline characteristics were comparable between the three groups ([Table 1](#t1-dddt-9-799){ref-type="table"}).

Among the 20 patients who completed 6 months of treatment with the high dose of Viron, two (10%) had a complete ETR, and two (10%) had a partial ETR. No virological response (no ≥2-log~10~ reduction of baseline virus load) was reported in the remaining 80% in group 3 ([Table 2](#t2-dddt-9-799){ref-type="table"}). Among the 20 patients who completed the full protocol with the medium dose, only one (5%) had a complete ETR. No patient in the group treated with the low dose showed a complete or partial ETR. There was a statistically significant linear association (*P*=0.043) between the higher dose and virological response.

Alanine aminotransferase levels decreased in group 3 (the high dose) at the end of 6 months of treatment by a mean −30.85 U/L (19.09) from baseline. This decrease was significantly greater than that in groups 2 and 3 (*F*=5.74, *P*=0.007, [Table 3](#t3-dddt-9-799){ref-type="table"}).

Health-related quality of life, as measured by the CLDQ score, was improved significantly only in the high dose group at the end of 6 months (*P*\<0.001, paired-sample *t*-test). The mean difference in scores from baseline was found to be significantly greater in the high dose group than in the low dose group (*F*=4.142, *P*=0.021, one-way analysis of variance, [Table 4](#t4-dddt-9-799){ref-type="table"}, and Tukey's post hoc analysis, [Table 5](#t5-dddt-9-799){ref-type="table"}). This significant improvement in CLDQ score was held true even after adjusting for the effect of both the baseline CLDQ score and the Child--Pugh score as two covariates by an ANCOVA model (*F*=2.9, *P*=0.029, [Table 6](#t6-dddt-9-799){ref-type="table"}).

No serious adverse effects attributable to therapy were reported in any of the three groups, apart from mild transient nausea, bloating, giddiness, and headache in two patients in the medium dose group and in three patients in the high dose group.

Conclusion
==========

We conclude that this herbal formula is potentially safe, and may offer some added clinical and quality of life benefits when used in the treatment of patients with chronic HCV infection. Further larger studies may be justified to evaluate the effects of this product as an add-on therapy to an all-oral combination of a directly acting antiviral drug protocol in the treatment of chronic HCV infection.
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###### 

Baseline characteristics

  Characteristic                                      Group 1 (n=20)      Group 2 (n=20)      Group 3 (n=20)
  --------------------------------------------------- ------------------- ------------------- -------------------
  Age, years (mean ± SD)                              47±12               48±12               48±12
  Sex, M/F                                            13/7                12/8                12/8
  Body mass index (kg/m^2^)                           29.8±6.2            29.7±6.8            28.7±7.3
  Baseline HCV RNA (log~10~ IU/mL), median (Q1--Q3)   5.35 (4.84--6.09)   5.43 (4.94--6.12)   5.63 (4.64--6.15)
  Baseline ALT, median (Q1--Q3)                       75 (44--203)        78 (48--198)        76 (43--216)
  Baseline Child--Pugh score, mean (SD)               7.067 (1.28)        7 (1.25)            7.1 (1.22)
  Interferon history (naïve/relapser/nonresponder)    17/2/1              16/3/1              17/2/1

**Abbreviations:** ALT, alanine aminotransferase; HCV, hepatitis C virus; SD, standard deviation.

###### 

Virological response at the end of 6 months of treatment according to Viron^®^ dose strength

                                                             ETR   Total        
  --------------------------- ---------------------- ------- ----- ------- ---- ----
  Treatment group             Viron one tablet bid   Count   20    0       0    20
  \% within treatment group   100%                   0%      0%    100%         
  Viron two tablets bid       Count                  19      0     1       20   
  \% within treatment group   95%                    0%      5%    100%         
  Viron three tablets bid     Count                  16      2     2       20   
  \% within treatment group   80%                    10%     10%   100%         
  Total                                              Count   55    2       3    60
  \% within treatment group   91.7%                  3.3%    5%    100%         

**Abbreviations:** bid, twice a day; ETR, virological response at the end of 6 months of treatment.

###### 

Changes in alanine aminotransferase from baseline

                            n    Mean       SD         *F*-test   *P*-value
  ------------------------- ---- ---------- ---------- ---------- -----------
  Viron one tablet bid      20   −10.5500   23.15275   5.74       0.007
  Viron two tablets bid     20   −10.6000   24.52153              
  Viron three tablets bid   20   −30.8500   19.08782              
  Total                     60   −17.3333   24.01036              

**Abbreviations:** bid, twice a day; SD, standard deviation.

###### 

Mean change in average Chronic Liver Disease Questionnaire overall score in the three dosage groups

                            n    Mean     SD        *F*-test   *P*-value
  ------------------------- ---- -------- --------- ---------- -----------
  Viron one tablet bid      20   0.2000   0.33477   4.142      0.021
  Viron two tablets bid     20   0.2985   0.35974              
  Viron three tablets bid   20   0.5050   0.33083              
  Total                     60   0.3345   0.35978              

**Abbreviations:** bid, twice a day; SD, standard deviation.

###### 

Tukey's honestly significant difference[a](#tfn6-dddt-9-799){ref-type="table-fn"}

  Treatment group           n    Subset for α=0.05   
  ------------------------- ---- ------------------- --------
  Viron one tablet bid      20   0.2000              
  Viron two tablets bid     20   0.2985              0.2985
  Viron three tablets bid   20                       0.5050
  Significance                   0.636               0.145

**Notes:** Means for groups in homogeneous subsets are displayed.

Uses a harmonic mean sample size of 20.

**Abbreviation:** bid, twice a day.

###### 

Tests of between-subject effects

  Source             Type III sum of squares                           df   Mean square   *F*-test   Significance level
  ------------------ ------------------------------------------------- ---- ------------- ---------- --------------------
  Corrected model    1.339[a](#tfn9-dddt-9-799){ref-type="table-fn"}   4    0.335         2.922      0.029
  Intercept          0.085                                             1    0.085         0.739      0.394
  CLDQ at baseline   0.330                                             1    0.330         2.885      0.095
  Child-Pugh score   0.091                                             1    0.091         0.797      0.376
  Group              0.781                                             2    0.390         3.410      0.040
  Error              6.298                                             55   0.115                    
  Total              14.350                                            60                            
  Corrected total    7.637                                             59                            

**Notes:** Dependent variable: CLDQ_diff.

*R*^2^=0.175 (adjusted *R*^2^=0.115).

**Abbreviations:** CLDQ, Chronic Liver Disease Questionnaire; df, degrees of freedom; CLDQ_diff, difference of CLDQ score from baseline.
